Treatment for Helicobacter pylori infection: An internet-assisted multicentre trial;Helicobacter pylori-behandling - Resultater og erfaringer med samarbeid via Internett

Tidsskrift for den Norske Laegeforening

Volumn 123, Issue 22, 2003, Pages 3214-3217

  Farup, Per G ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Medisinsk Avdeling   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE; TETRACYCLINE; ANTIINFECTIVE AGENT; ANTIULCER AGENT;

ADULT; AGE; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HEALTH CARE QUALITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORWAY; OPEN STUDY; OUTPATIENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; AGED; COMPARATIVE STUDY; DRUG COMBINATION; MICROBIOLOGY; MIDDLE AGED; STOMACH ULCER;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTERNET; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; RANITIDINE; STOMACH ULCER; TETRACYCLINE;

EID: 1242287559     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997; 41: 8-13.
2. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330-8.
3. Hunt R, Thomson AB. Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol 1998; 12: 31-41.
4. Asaka M, Satoh K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y et al. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001; 6: 177-86.
5. Malfertheiner P, Mégraud F, O'Morain C, Hungin APS, Jones R, Axon A et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002; 16: 167-80.
6. Olafsson S, Berstad A. Therapy and diagnostic tests used for Helicobacter pylori infection in the Scandinavian countries in 1998. Scand J Gastroenterol 1999; 34: 849-55.
7. Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001; 96: 1335-9.
8. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36: 690-700.
9. Farup PG, Tholfsen J, Wetterhus S, Torp R, Høie O, Lange OJ. A comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Scand J Gastroenterol 2002; 37: 1374-9.
10. Farup PG, Lange OJ, Tholfsen J, Høeg V, Wetterhus S. The effect of Helicobacter pylori retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends of first-line therapy. J Clin Gastroenterol 2002; 35: 379-82.
11. Farup PG, Skar V. Collaboration by use of Internet yields data of high quality and detects non uniform management of patients with Helicobacter pylori infection. Scand J Gastroenterol 2002; 37: 1466-70.
12. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week - a meta-analysis of efficacy. Aliment Pharmacol Ther 2000; 14: 1141-50.
13. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-28.
14. Van Oijen AH, Verbeek AL, Jansen JB, De Boer WA. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. Aliment Pharmacol Ther 2000; 14: 991-9.
15. Janssen MJR, Van Oijen AH, Verbeek ALM, Jansen JBM, De Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther 2001; 15: 613-24.
16. Gisbert JP, Pajares JM, Valle J. Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review. Helicobacter 1999; 4: 58-66.
17. Penston JG, McColl KE. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-43.
18. Sung JJ, Chan FK, Wu JC, Leung WK, Suen R, Ling TK et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Aliment Pharmacol Ther 1999; 13: 1079-84.
19. Wreiber K, Olsson-Liljequist B, Engstrand L. Development of resistant Helicobacter pylori in Sweden. Tendency toward increasing resistance to clarithromycin. Läkartidningen 1999; 96: 582-4.
20. Midolo PD, Lambert JR, Kerr TG, Tee W. In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1999; 18: 832-4.
21. Houben MH, Van Der BD, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-55.
22. Savarino V, Zentilin P, Pivari M, Bisso G, Raffaella MM, Bilardi C et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 893-900.
23. Wong BC, Wong WM, Wang WH, Fung FM, Lai KC, Chu KM et al. One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. Aliment Pharmacol Ther 2001; 15: 403-9.
24. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161: 1217-20.
25. De Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ 2000; 320: 31-4.
26. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment Pharmacol Ther 2001; 15: 1017-22.
27. McNamara D, O'Morain C. Consensus guidelines: agreement and debate surrounding the optimal management of Helicobacter pylori infection. Can J Gastroenterol 2000; 14: 511-7.
28. Kiuchi T, Ohashi Y, Konishi M, Bandai Y, Kosuge T, Kakizoe T. A World Wide Web-based user interface for a data management system for use in multi-institutional clinical trials - development and experimental operation of an automated patient registration and random allocation system. Control Clin Trials 1996; 17: 476-93.
29. Foster NL, Gombosi E, Teboe C, Little RJ. Balanced centralized and distributed database design in a clinical research environment. Stat Med 2000; 19: 1531-44.
30. Curley RM, Evans RL, Kaylor J, Pogash RM, Chinchilli VM. Development and deployment of an internet-based data management system for use by the asthma clinical research network. Control Clin Trials 2001; 22: S135-S55.
31. Kelly MA, Oldham J. The Internet and randomised controlled trials. Int J Med Inf 1997; 47: 91-9.
32. Santoro E, Nicolis E, Franzosi MG, Tognoni G. Internet for clinical trials: past, present, and future. Control Clin Trials 1999; 20: 194-201.
33. Foster NL. New opportunities to study real-word patient management. Scand J Gastroenterol 2003; 38: 341-2.